Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial

Steven M. Opal, Pierre Francois Laterre, Bruno Francois, Steven P. LaRosa, Derek C. Angus, Jean Paul Mira, Xavier Wittebole, Thierry Dugernier, Dominique Perrotin, Mark Tidswell, Luis Jauregui, Kenneth Krell, Jan Pachl, Takeshi Takahashi Claus Peckelsen, Edward Cordasco, Chia Sheng Chang, Sandra Oeyen, Naoki Aikawa, Tatsuya Maruyama, Roland ScheinAndre C. Kalil, Marc Van Nuffelen, Melvyn Lynn, Daniel P. Rossignol, Jogadish Gogate, Mary B. Roberts, Janice L. Wheeler, Jean Louis Vincent

Research output: Contribution to journalArticlepeer-review

627 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial'. Together they form a unique fingerprint.

Medicine & Life Sciences